Axsome (AXSM) Begins Dosing in Depression Study on Sunosi

Axsome Therapeutics, Inc. (AXSM) announced that it has dosed the first patient in the phase III PARADIGM study evaluating its investigational therapy, solriamfetol, for treating major depressive disorder (MDD). Shares of the company were up 6% on Mar 19, following the announcement of the news.Solriamfetol is marketed in the United States under the trade name, Sunosi, for the treatment of narcolepsy.The double-blind and placebo-controlled phase III study will evaluate the safety and efficacy of solriamfetol ...